Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Andrew J. Syder"'
Publikováno v:
Viruses, Vol 2, Iss 8, Pp 1718-1733 (2010)
Recent progress in defining the molecular mechanisms of Hepatitis C Virus (HCV) entry affords the opportunity to exploit new viral and host targets for therapeutic intervention. Entry inhibitors would limit the expansion of the infected cell reservoi
Externí odkaz:
https://doaj.org/article/e30b57a0bcbd4bc78fa75dfcc042a7d2
Autor:
Yeming Xie, Angela F. Herrera, Wen Li, Ashley Olseen, Andrew J. Syder, Andrew Outland, Jill Wykosky, Brian A. Perrino, Cristina Alexandru
Publikováno v:
Journal of Muscle Research and Cell Motility
Coordinated gastric smooth muscle contraction is critical for proper digestion and is adversely affected by a number of gastric motility disorders. In this study we report that the secreted protein Mfge8 (milk fat globule-EGF factor 8) inhibits the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8537f9f0bc4ea3b64f2437022445e414
https://pubmed.ncbi.nlm.nih.gov/34085177
https://pubmed.ncbi.nlm.nih.gov/34085177
Autor:
Emily A. Whitfield, Linda J Fothergill, Andrew J. Syder, Jill Wykosky, Sebastian G.B. Furness, John B. Furness, Eun Ji Yoo, Mitchell T Ringuet, Andrea Fanjul, Ruslan V Pustovit
Publikováno v:
Neurogastroenterology & Motility. 33
BACKGROUND: Dopamine receptor 2 (DRD2) and ghrelin receptor (GHSR1a) agonists both stimulate defecation by actions at the lumbosacral defecation center. Dopamine is in nerve terminals surrounding autonomic neurons of the defecation center, whereas gh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc67aa04d8cacb792a9af6d231a0e05
https://doi.org/10.1111/nmo.14051
https://doi.org/10.1111/nmo.14051
Autor:
Deborah L Diamond, Andrew J Syder, Jon M Jacobs, Christina M Sorensen, Kathie-Anne Walters, Sean C Proll, Jason E McDermott, Marina A Gritsenko, Qibin Zhang, Rui Zhao, Thomas O Metz, David G Camp, Katrina M Waters, Richard D Smith, Charles M Rice, Michael G Katze
Publikováno v:
PLoS Pathogens, Vol 6, Iss 1, p e1000719 (2010)
Proteomic and lipidomic profiling was performed over a time course of acute hepatitis C virus (HCV) infection in cultured Huh-7.5 cells to gain new insights into the intracellular processes influenced by this virus. Our proteomic data suggest that HC
Externí odkaz:
https://doaj.org/article/ba61ce4400a44ab3b967b7abeea79649
Autor:
Jeffrey McKelvy, Robert T. Schooley, Haihong Zhu, Andrew J. Syder, Haekyung Lee, Flossie Wong-Staal, David L. Wyles
Publikováno v:
The Journal of Infectious Diseases. 205:656-662
ITX 5061 is a scavenger receptor B1 antagonist that has entered phase 1 clinical trials in hepatitis C virus (HCV)-infected humans. We evaluated ITX 5061 in combination with interferon-α, ribavirin, and HCV protease and polymerase inhibitors in a ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4457c82e25bd1dec8086bcc9aa11a26
https://doi.org/10.1093/infdis/jir802
https://doi.org/10.1093/infdis/jir802
Autor:
Jeffrey McKelvy, Joe Grove, Stephine Chow, Jane A. McKeating, Andrew J. Syder, Eric Soulier, Haekyung Lee, James W. MacDonald, Julia Chang, Flossie Wong-Staal, Thomas F. Baumert, Mirjam B. Zeisel
Publikováno v:
Journal of Hepatology
Journal of Hepatology, Elsevier, 2011, 54 (1), pp.48-55. ⟨10.1016/j.jhep.2010.06.024⟩
Journal of Hepatology, Elsevier, 2011, 54 (1), pp.48-55. ⟨10.1016/j.jhep.2010.06.024⟩
BACKGROUND AND AIMS: ITX 5061 is a clinical stage small molecule compound that promotes high-density lipoprotein (HDL) levels in animals and patients by targeting the scavenger receptor BI protein pathway. Since SR-BI is a known co-receptor for HCV i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5950c56079ac8ec59f018672f68f1bc0
https://doi.org/10.1016/j.jhep.2010.06.024
https://doi.org/10.1016/j.jhep.2010.06.024
Publikováno v:
Viruses
Viruses, Vol 2, Iss 8, Pp 1718-1733 (2010)
Viruses, Vol 2, Iss 8, Pp 1718-1733 (2010)
Recent progress in defining the molecular mechanisms of Hepatitis C Virus (HCV) entry affords the opportunity to exploit new viral and host targets for therapeutic intervention. Entry inhibitors would limit the expansion of the infected cell reservoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006ebdb3095f1e2010cb1d491fd1fb12
http://europepmc.org/articles/PMC3185726
http://europepmc.org/articles/PMC3185726
Autor:
Charles M. Rice, Kimberly D. Ritola, Kathy Mu, Andrew J. Syder, Kartik Trehan, Salman R. Khetani, Alexander Ploss, Sangeeta N. Bhatia, V. Gaysinskaya, Christopher T. Jones
Publikováno v:
Proceedings of the National Academy of Sciences. 107:3141-3145
Hepatitis C virus (HCV) remains a major public health problem, affecting approximately 130 million people worldwide. HCV infection can lead to cirrhosis, hepatocellular carcinoma, and end-stage liver disease, as well as extrahepatic complications suc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81ac8754126d21639829565ded68b12
https://doi.org/10.1073/pnas.0915130107
https://doi.org/10.1073/pnas.0915130107
Autor:
Benno Wölk, Paul D. Bieniasz, Andrew J. Syder, Donna M. Tscherne, Theodora Hatziioannou, Thomas von Hahn, Matthew J. Evans, Charles M. Rice, Jane A. McKeating, Maryline Panis
Publikováno v:
Nature. 446:801-805
Hepatitis C virus (HCV) is a leading cause of cirrhosis and liver cancer worldwide. A better understanding of the viral life cycle, including the mechanisms of entry into host cells, is needed to identify novel therapeutic targets. Although HCV entry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946699529c35e55337a462a0ef233efd
https://doi.org/10.1038/nature05654
https://doi.org/10.1038/nature05654
Autor:
Robert E. Lanford, Charles M. Rice, Jane A. McKeating, Thomas Vanwolleghem, Andrew J. Syder, Stephen M. Feinstone, Marian E. Major, Alexander Ploss, Brett D. Lindenbach, Geert Leroux-Roels, Philip Meuleman
Publikováno v:
Proceedings of the National Academy of Sciences. 103:3805-3809
Hepatitis C virus (HCV) is a major cause of chronic liver disease, frequently progressing to cirrhosis and increased risk of hepatocellular carcinoma. Current therapies are inadequate and progress in the field has been hampered by the lack of efficie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::928382af981c358c5eb145144da21052
https://doi.org/10.1073/pnas.0511218103
https://doi.org/10.1073/pnas.0511218103